The new generation of molecular urological diagnostics
The oncology diagnostics market is evolving towards non-invasive, more precise and scalable molecular solutions adapted to personalized medicine.
Molecular diagnostics
Personalized medicine
Scalable platform
Urine miRNA biomarkers analyzed through high-sensitivity RT-qPCR technology.
Tools designed to support clinical and therapeutic decision-making.
Technology adaptable to hospitals, laboratories and international diagnostic networks.
>90%
33%
Non-invasive
$9.2B
Clinical precision
Lower cost
Urine sample
Market opportunity
An unmet medical and economic need
Bladder cancer has a high recurrence rate and requires long-term monitoring, creating a significant burden for patients, hospitals and healthcare systems.
+550,000
+70%
€150,000
annual global cases
recurrence rate
cost per patient
A significant global market with recurring needs for diagnosis and monitoring.
High recurrence multiplies the volume of follow-up procedures and accumulated costs.
One of the oncology indications with the highest accumulated economic burden..
The result: healthcare systems under pressure, saturated hospitals and a clear opportunity for non-invasive, precise and cost-effective molecular alternatives.
PROPRIETARY TECHNOLOGY
BlaDimiR Platform
Danae Urogenomics is developing a family of urine-based miRNA biomarker solutions with applications in diagnosis, monitoring and therapy response prediction.
Non-invasive diagnosis and monitoring of bladder cancer
Urine-based miRNA biomarkers
High sensitivity and specificity
Designed for clinical practice
Therapy response prediction
Advanced assessment of combination therapies
Supports clinical decision-making
Personalized medicine approach
Value for hospitals and networks
miRNAs + cytokines
Complex clinical contexts
Pipeline scalability
